176 related articles for article (PubMed ID: 23307976)
1. Everolimus causing severe hypertriglyceridemia and acute pancreatitis.
Subramaniam S; Zell JA; Kunz PL
J Natl Compr Canc Netw; 2013 Jan; 11(1):5-9. PubMed ID: 23307976
[TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET).
De Gennaro Colonna V; Pavanello C; Rusconi F; Sartore-Bianchi A; Siena S; Castelnuovo S; Sirtori CR; Mombelli G
J Clin Pharm Ther; 2018 Feb; 43(1):114-116. PubMed ID: 28730672
[TBL] [Abstract][Full Text] [Related]
3. [Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor].
De Carlos Artajo J; Castro Unanua N; Muruzábal Huarte E; Vera García R; Irigaray Echarri A; Zubiría Gortázar J; Anda Apiñániz E
An Sist Sanit Navar; 2020 Apr; 43(1):103-106. PubMed ID: 32242549
[TBL] [Abstract][Full Text] [Related]
4. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
5. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
6. Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
[TBL] [Abstract][Full Text] [Related]
7. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
Vernieri C; Pusceddu S; Fucà G; Indelicato P; Centonze G; Castagnoli L; Ferrari E; Ajazi A; Pupa S; Casola S; Foiani M; Mazzaferro V; Pruneri G; Milione M; de Braud F
Int J Cancer; 2019 Apr; 144(7):1704-1712. PubMed ID: 30520016
[TBL] [Abstract][Full Text] [Related]
8. Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report.
Sibertin-Blanc C; Norguet E; Duluc M; Louis G; Seitz JF; Dahan L
BMC Res Notes; 2013 Nov; 6():471. PubMed ID: 24245774
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors.
Carbonnaux M; Molin Y; Souquet PJ; Tantin A; Lombard-Bohas C; Walter T
Invest New Drugs; 2014 Dec; 32(6):1308-10. PubMed ID: 25119297
[TBL] [Abstract][Full Text] [Related]
10. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
11. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G
Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065
[TBL] [Abstract][Full Text] [Related]
12. [Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
Lombard-Bohas C; Cariou B; Vergès B; Coriat R; N'guyen T; François E; Hammel P; Niccoli P; Hentic O
Bull Cancer; 2014 Feb; 101(2):175-83. PubMed ID: 24557872
[TBL] [Abstract][Full Text] [Related]
13. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
[TBL] [Abstract][Full Text] [Related]
14. Everolimus for the treatment of pancreatic neuroendocrine tumors.
Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.
Yao JC; Phan AT; Jehl V; Shah G; Meric-Bernstam F
Cancer Res; 2013 Mar; 73(5):1449-53. PubMed ID: 23436795
[TBL] [Abstract][Full Text] [Related]
16. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
Capdevila J; Tabernero J
Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
Procopio G; Pusceddu S; Buzzoni R
Tumori; 2012; 98(3):394. PubMed ID: 22825518
[No Abstract] [Full Text] [Related]
18. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.
Nakayama Y; Ikeda M; Kojima M; Goto K; Hara M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Okusaka T
Chemotherapy; 2013; 59(1):74-8. PubMed ID: 23867634
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.
Yao J; Wang JY; Liu Y; Wang B; Li YX; Zhang R; Wang LS; Liu L
Med Oncol; 2014 Dec; 31(12):251. PubMed ID: 25395378
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]